

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087382 A1

- (51) International Patent Classification⁷: C12N 15/86 (74) Agents: WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).
- (21) International Application Number: PCT/GB03/01585 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 11 April 2003 (11.04.2003) (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0208390.5 11 April 2002 (11.04.2002) GB
- (71) Applicant (*for all designated States except US*): UNIVERSITY COLLEGE LONDON [GB/GB]; Gower Street, London WC1E 9BT (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): COFFIN, Robert, Stuart [GB/GB]; 70 Milton Street, Abington, Oxfordshire OX14 4RX (GB). BOOTH, Matthew, James [GB/GB]; The Windeyer Institute, 46 Cleveland Street, London W1P 6DP (GB).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/087382 A1

(54) Title: ADENO-ASSOCIATED VIRUS PRODUCER SYSTEM

(57) Abstract: The present invention provides the use of a replication competent herpes virus which (a) lacks a functional wild-type HSV ICP27 gene; and (b) comprises an ICP27 gene encoding an ICP27 protein which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27 in the production of an adeno-associated virus (AAV) vector.

INTERNATIONAL SEARCH REPORT

PCT/GB 03/01585

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SOLIMAN TARIK M ET AL: "Shuttling of the herpes simplex virus type 1 regulatory protein ICP27 between the nucleus and cytoplasm mediates the expression of late proteins." JOURNAL OF VIROLOGY, vol. 71, no. 12, December 1997 (1997-12), pages 9188-9197, XP002247080 ISSN: 0022-538X page 9195 figure 1 ---	1-27

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *'Z' document member of the same patent family

Date of the actual completion of the international search

10 July 2003

Date of mailing of the international search report

24/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Guarinos Viñals, E

INTERNATIONAL SEARCH REPORT

PCT/GB 03/01585

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CONWAY ET AL: "Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by herpes simplex virus type 1 amplicon expressing rep and cap"</p> <p>JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 11, November 1997 (1997-11), pages 8780-8789, XP002102271 ISSN: 0022-538X page 8785, right-hand column page 8788, left-hand column</p>	1-27
A	<p>COFFIN R S ET AL: "Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors"</p> <p>GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 3, no. 10, October 1996 (1996-10), pages 886-891, XP002108600 ISSN: 0969-7128 figure 1</p>	10,16
A	<p>ZHANG X ET AL: "HIGH-TITER RECOMBINANT ADENO-ASSOCIATED VIRUS PRODUCTION FROM REPLICATING AMPLICONS AND HERPES VECTORS DELETED FOR GLYCOPROTEIN H"</p> <p>HUMAN GENE THERAPY, XX, XX, vol. 10, no. 15, 10 October 1999 (1999-10-10), pages 2527-2537, XP000906820 ISSN: 1043-0342 figure 1</p>	9

INTERNATIONAL SEARCH REPORT

SCT/GB 03/01585

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: 1-27 partially
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 03 01585

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-27 partially

Present claims 1-27 relate to a ICP27 protein defined by reference to a desirable characteristic or property, namely its capacity to allow herpes virus replication and its reduced ability to inhibit RNA splicing compared to wild type ICP27.

The claims cover all ICP27 proteins having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such proteins. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the protein by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the ICP27 proteins comprising the double substitutions specified in page 9, lines 9-20 of the description: R480H + S334L; R480H + V487I; R480H + V496I

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

SEQUENCE LISTING

<110> UNIVERSITY COLLEGE LONDON
<120> ADENO-ASSOCIATED VIRUS PRODUCER SYSTEM
<130> N.85297A
<150> GB 0208390.5
<151> 2002-04-11
<160> 2
<170> PatentIn version 3.1
<210> 1
<211> 1539
<212> DNA
<213> Herpes simplex virus

<400> 1
atggcgactg acattgatat gctaattgac ctggcctgg acctctccga cagcgatctg 60
gacgaggacc cccccc gagcc ggccggagac cgccgcgacg accttggaaatc ggacagcaac 120
ggggagtggtt cctcgtcgga cgaggacatg gaagaccccc acggagagga cggaccggag 180
ccgataactcg acgcccgtcg cccggcggtc cgcccgatctc gtccagaaga ccccgccgta 240
cccacagcaccc agacgcctcg tccgacggag cggcaggggcc ccaacgatcc tcaaccagcg 300
ccccacagtg tttttttttt cccggggggcc cggcgaccgt ttgtttttttt cggccggcc 360
ggggggcaagg tggcccgccct ccaacccccca ccgacccaaag cccagcctgc cccggccgga 420
cgcccggtggc gtcgcagggg tcgggggtcgcc ggtggtcccg gggccgccga tggtttttttcc 480
gaccccccggcc ggcgtgcggcc cagaaccaat cgcaacccgg ggggaccccg ccccgccggcg 540
gggtggacgg acggcccccgg cgcccccattt ggcgaggcggt ggcgcggaaag tgagcagcccc 600
gacccacccgg gaggcccgccg gacacggagc gtgcgcacaag caccccccgg cgtttttttttt 660
ctggcgatttgc ccccccggcc cgccggaccccg cccggccggcc cccggagcg aaaggcgcccc 720
gcccggccaca ccatcgacgc caccacgcgg ttgggtccgtc gctccatctc cgagcgccg 780
gcgggtcgacc gcatcagcga gagtttcggc cgcagcgcac aggtcatgca cgaccccttt 840
ggggggcagc cgttttccgc cgcaaatagc ccctggggcc cgggtgtggc gggccaagga 900
ggggcccttttgc acgcccggac cagacgggtc ttctggggaaa ctttgggtcgcc ccacggcccg 960
agccctatc gcacttttgc cggcaatccct cggggccgcat cgaccgcggaa ggccatgcgc 1020
gactgcgtgc tgcgcacaaga aaatttcatc gaggcgctgg cctccggccga cgagacgctg 1080
gcgtggtgca agatgtgcat ccaccacaac ctggcgatctc gccccccggg ccccaattatc 1140
gggacggcccg cggcggtgtc ggataacccctc gccacgcggcc tgcggccctt tctccagtgc 1200
tacctgaagg cgccggccctt gtgcggccgt gacgaactgt gttcgccggcg gctgttccgtggcg 1260

2

gacattaagg	acattgcac	cttcgtgtt	gtcattctgg	ccaggctcgc	caaccgcgtc	1320
gagcggtggcg	tcgcggagat	cgactacgcg	acccttggtg	tcggggtcgg	agagaagatg	1380
catttctacc	tccccggggc	ctgcatggcg	ggcctgatcg	aaatcctaga	cacgcaccgc	1440
caggagtgtt	cgagtcgtgt	ctgcgagttg	acggccagtc	acatcgtcgc	ccccccgtac	1500
gtgcacggca	aatatttta	ttgcaactcc	ctgttttag			1539

<210> 2

<211> 512

<212> PRT

<213> Herpes simplex virus

<400> 2

Met Ala Thr Asp Ile Asp Met Leu Ile Asp Leu Gly Leu Asp Leu Ser						
1	5	10	15			

Asp Ser Asp Leu Asp Glu Asp Pro Pro Glu Pro Ala Glu Ser Arg Arg						
20	25	30				

Asp Asp Leu Glu Ser Asp Ser Asn Gly Glu Cys Ser Ser Ser Asp Glu						
35	40	45				

Asp Met Glu Asp Pro His Gly Glu Asp Gly Pro Glu Pro Ile Leu Asp						
50	55	60				

Ala Ala Arg Pro Ala Val Arg Pro Ser Arg Pro Glu Asp Pro Gly Val						
65	70	75	80			

Pro Ser Thr Gln Thr Pro Arg Pro Thr Glu Arg Gln Gly Pro Asn Asp						
85	90	95				

Pro Gln Pro Ala Pro His Ser Val Trp Ser Arg Leu Gly Ala Arg Arg						
100	105	110				

Pro Ser Cys Ser Pro Glu Arg His Gly Gly Lys Val Ala Arg Leu Gln						
115	120	125				

Pro Pro Pro Thr Lys Ala Gln Pro Ala Arg Gly Gly Arg Arg Gly Arg						
130	135	140				

Arg Arg Gly Arg Gly Arg Gly Pro Gly Ala Ala Asp Gly Leu Ser						
145	150	155	160			

Asp Pro Arg Arg Arg Ala Pro Arg Thr Asn Arg Asn Pro Gly Gly Pro						
165	170	175				

Arg Pro Gly Ala Gly Trp Thr Asp Gly Pro Gly Ala Pro His Gly Glu						
180	185	190				

Ala Trp Arg Gly Ser Glu Gln Pro Asp Pro Pro Gly Gly Pro Arg Thr						
195	200	205				

Arg Ser Val Arg Gln Ala Pro Pro Pro Leu Met Thr Leu Ala Ile Ala						
210	215	220				

Pro Pro Pro Ala Asp Pro Arg Ala Pro Pro Glu Arg Lys Ala Pro						
225	230	235	240			

Ala Ala Asp Thr Ile Asp Ala Thr Thr Arg Leu Val Leu Arg Ser Ile						
245	250	255				

3

Ser Glu Arg Ala Ala Val Asp Arg Ile Ser Glu Ser Phe Gly Arg Ser
260 265 270

Ala Gln Val Met His Asp Pro Phe Gly Gly Gln Pro Phe Pro Ala Ala
275 280 285

Asn Ser Pro Trp Ala Pro Val Leu Ala Gly Gln Gly Gly Pro Phe Asp
290 295 300

Ala Glu Thr Arg Arg Val Ser Trp Glu Thr Leu Val Ala His Gly Pro
305 310 315 320

Ser Leu Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala Ala Ser Thr Ala
325 330 335

Lys Ala Met Arg Asp Cys Val Leu Arg Gln Glu Asn Phe Ile Glu Ala
340 345 350

Leu Ala Ser Ala Asp Glu Thr Leu Ala Trp Cys Lys Met Cys Ile His
355 360 365

His Asn Leu Pro Leu Arg Pro Gln Asp Pro Ile Ile Gly Thr Ala Ala
370 375 380

Ala Val Leu Asp Asn Leu Ala Thr Arg Leu Arg Pro Phe Leu Gln Cys
385 390 395 400

Tyr Leu Lys Ala Arg Gly Leu Cys Gly Leu Asp Glu Leu Cys Ser Arg
405 410 415

Arg Arg Leu Ala Asp Ile Lys Asp Ile Ala Ser Phe Val Phe Val Ile
420 425 430

Leu Ala Arg Leu Ala Asn Arg Val Glu Arg Gly Val Ala Glu Ile Asp
435 440 445

Tyr Ala Thr Leu Gly Val Gly Val Gly Glu Lys Met His Phe Tyr Leu
450 455 460

Pro Gly Ala Cys Met Ala Gly Leu Ile Glu Ile Leu Asp Thr His Arg
465 470 475 480

Gln Glu Cys Ser Ser Arg Val Cys Glu Leu Thr Ala Ser His Ile Val
485 490 495

Ala Pro Pro Tyr Val His Gly Lys Tyr Phe Tyr Cys Asn Ser Leu Phe
500 505 510